Skip to Content

Breast Cancer Trials

Impact of an In-Visit Decision Aid on Uniformed Decision Making for Contralateral Prophylactic Mastectomy
Aims: To determine whether using an online decision intervention directly with patients will increase patient knowledge resulting in fewer patients making uninformed decisions to undergo contralateral prophylactic mastectomy.
Diagnosis: Breast Cancer- Participants must enroll prior to breast surgery
Principal Investigator: Katherine Yao, MD
IRB Approval Number: EH17-045
Sponsor: NorthShore University HealthSystem
Contact:  Interested patients may contact Sarah Rabbitt, RN, CCRP at 847.570.1681 or srabbitt@northshore.org or Sandra Simovic at 847.570.4227, ssimovic@northshore.org
Open to Enrollment: Yes

S1418/BR006: A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy       
Aims: The purpose of this study is compare the usual approach (which may include no more treatment, additional chemotherapy and/or radiation) to receiving an experimental drug pembrolizumabfor 1 year. 
Diagnosis: Breast Cancer
Principal Investigator: Poornima Saha, MD
IRB Approval Number: EH20-025
Sponsor: Southwest Oncology Group
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

 A011202: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3N1) who have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Aims: This randomized phase III trial studies axillary lymph node dissection to see how well it works compared to axillary radiation therapy in treating patients with node-positive breast cancer treated with neoadjuvant chemotherapy followed by surgery. Lymph node dissection may remove cancer cells that have spread to nearby lymph nodes in patients with breast cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. This study will evaluate whether radiation therapy is as effective as lymph node dissection. 
Diagnosis: Breast Cancer, Clinical Stage II-IIIA
Principal Investigator: Catherine Pesce, MD
IRB Approval Number: EH15-297
Sponsor: Alliance for Clinical Trials in Oncology
Contact: Interested patients may contact  Sarah Rabbitt, RN at 847.570.1681, srabbitt@northshore.org or Sandra Simovic at 847.570.4227, ssimovic@northshore.org
Open to Enrollment: Yes

NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel / Trastuzumab / Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Aims: The purpose is to see if patients if the addition of atezolizumab would be helpful in controlling cancer.
Diagnosis: Breast cancer
Principal Investigator: Poornima Saha, MD
IRB Approval Number: EH20-365
Sponsor: NRG Oncology
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

EA1181: The CompassHER2 Trials (COMprehensive us of Pathological Response ASSessment to optimize therapy in HER2-positive breast cancer): CompassHER2 Residual Disease (RD), a double-blinded, phase III randomized trial of T-DM1 and placebo compared with T-DM1 adn tucatinib
Aims: The purpose is to see if patients who have no cancer after intial therapy and surgery need additional chemotherapy or would targeted treatments be enough.
Diagnosis: Breast cancer
Principal Investigator: Poornima Saha, MD
IRB Approval Number: EH21-154
Sponsor: Alliance for Clinical Trials in Oncology
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

A011801: (CompassHERCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response.
Aims: The purpose is to see if adding tucabinib to the standard treatment of T-DM1 is better than T-DM1 alone in preventing your cancer from returning. 
Diagnosis: Breast cancer
Principal Investigator: Poornima Saha, MD
IRB Approval Number: EH21-013
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

 UC16-0403: A Randomized, Placebo-Controlled, Double-Blind, Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel (nab-paclitaxel, Abraxane) with or without Mifepristone for Advanced, Glucocorticoid, Receptor-positive, Triple Negative Breast Cancer
Aims: The purpose of this study is to compare the addition of mifepristone or placebo to chemotherapy for women who have a diagnosis of triple negative breast cancer that has recurred.
Diagnosis: Triple negative breast cancer
Principal Investigator: Poornima Saha, MD
IRB Approval Number: EH17-242
Sponsor: University of Chicago
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes